JP6596090B2 - レチノイン酸受容体ベータ（ＲＡＲβ）アゴニストとしてのビシクロヘテロアリール−ヘテロアリール−安息香酸化合物 - Google Patents

レチノイン酸受容体ベータ（ＲＡＲβ）アゴニストとしてのビシクロヘテロアリール−ヘテロアリール−安息香酸化合物 Download PDF

Info

Publication number
JP6596090B2
JP6596090B2 JP2017532660A JP2017532660A JP6596090B2 JP 6596090 B2 JP6596090 B2 JP 6596090B2 JP 2017532660 A JP2017532660 A JP 2017532660A JP 2017532660 A JP2017532660 A JP 2017532660A JP 6596090 B2 JP6596090 B2 JP 6596090B2
Authority
JP
Japan
Prior art keywords
neuropathy
compound
bhba
independently
damage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017532660A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017537967A (ja
JP2017537967A5 (enExample
Inventor
デヴィッド ボースウィック，アラン
トレヴァー ミルズ，マーク
テレサ ブラウン，ジェーン
パトリック トーマス コーコラン，ジョナサン
カストロ ヴァスコンセロス ゴンカルヴェス，マリア ベアトリス デ
バレット カリンドジャン，サーキス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kings College London
Original Assignee
Kings College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kings College London filed Critical Kings College London
Publication of JP2017537967A publication Critical patent/JP2017537967A/ja
Publication of JP2017537967A5 publication Critical patent/JP2017537967A5/ja
Application granted granted Critical
Publication of JP6596090B2 publication Critical patent/JP6596090B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2017532660A 2014-12-17 2015-12-16 レチノイン酸受容体ベータ（ＲＡＲβ）アゴニストとしてのビシクロヘテロアリール−ヘテロアリール−安息香酸化合物 Active JP6596090B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201422472 2014-12-17
GB1422472.9 2014-12-17
PCT/EP2015/080029 WO2016097004A1 (en) 2014-12-17 2015-12-16 BICYCLOHETEROARYL-HETEROARYL-BENZOIC ACID COMPOUNDS AS RETINOIC ACID RECEPTOR BETA (RARβ) AGONISTS

Publications (3)

Publication Number Publication Date
JP2017537967A JP2017537967A (ja) 2017-12-21
JP2017537967A5 JP2017537967A5 (enExample) 2019-01-24
JP6596090B2 true JP6596090B2 (ja) 2019-10-23

Family

ID=55027725

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017532660A Active JP6596090B2 (ja) 2014-12-17 2015-12-16 レチノイン酸受容体ベータ（ＲＡＲβ）アゴニストとしてのビシクロヘテロアリール−ヘテロアリール−安息香酸化合物

Country Status (11)

Country Link
US (4) US9994559B2 (enExample)
EP (1) EP3233842B1 (enExample)
JP (1) JP6596090B2 (enExample)
KR (1) KR102526625B1 (enExample)
CN (1) CN107207488B (enExample)
AU (1) AU2015367531B2 (enExample)
BR (1) BR112017012588B8 (enExample)
CA (1) CA2970574C (enExample)
ES (1) ES3029609T3 (enExample)
IL (1) IL252882B (enExample)
WO (1) WO2016097004A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3233842B1 (en) * 2014-12-17 2025-03-26 King's College London Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (rarb) agonists
GB201610867D0 (en) * 2016-06-22 2016-08-03 King S College London Crystalline forms of a therapeutic compound and processes for their preparation
CN111892591A (zh) * 2019-05-06 2020-11-06 南京科技职业学院 一种维奈托克关键中间体的合成方法
GB201907647D0 (en) * 2019-05-30 2019-07-17 King S College London Therapeutic methods
CN115427401B (zh) 2020-05-29 2025-04-11 巴斯夫欧洲公司 取代4-(n′-羟基甲脒基)苯甲酸的制备
CN112552252B (zh) * 2020-09-30 2024-01-02 浙江美诺华药物化学有限公司 一种氟雷拉纳中间体的制备方法
CN113264832A (zh) * 2021-05-13 2021-08-17 南京爱可德夫科技开发有限公司 一种合成高纯度2-氟-4-溴苯甲酸叔丁酯的方法
CN116640071B (zh) * 2023-05-04 2024-08-30 四川青木制药有限公司 一种制备2-甲基4-甲醛肟基苯甲酸及其酯类衍生物的方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9709475A (es) 1995-06-07 1998-02-28 Nippon Shinyaku Co Ltd Derivados de pirrol y composicion medicinal.
JP3964478B2 (ja) 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
CN1211361C (zh) 1996-03-18 2005-07-20 卫材株式会社 含有稠环的羧酸衍生物
JPH10158192A (ja) 1996-10-03 1998-06-16 Eisai Co Ltd 移植片対宿主疾患（ｇｖｈｄ）の治療および臓器移植時の移植片拒絶反応抑制のための医薬組成物
GB9907461D0 (en) 1999-03-31 1999-05-26 King S College London Neurite regeneration
US6355669B1 (en) 1997-10-22 2002-03-12 Eisai Co., Ltd. Retinoic acid agonists as preventive and therapeutic agents for nephritis
JP2000154150A (ja) * 1997-10-22 2000-06-06 Eisai Co Ltd 腎炎予防・治療剤としてのレチノイン酸アゴニスト
RU2241709C2 (ru) * 1999-07-09 2004-12-10 Орто-Макнейл Фармасьютикал, Инк. Производные азотсодержащих гетероциклических соединений и способ лечения расстройств, характеризующихся поражением нейронов
US20020048580A1 (en) * 2000-06-07 2002-04-25 Institut National De La Sante Et De La Recherche Medicale Method of inducing lung branching
CA2449544A1 (en) 2001-06-08 2002-12-19 Cytovia, Inc. Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs
JP2003081832A (ja) 2001-06-26 2003-03-19 Takeda Chem Ind Ltd レチノイド関連受容体機能調節剤
WO2003062230A1 (en) * 2002-01-21 2003-07-31 Eisai Co., Ltd. Conbinatorial library of heterocycle compounds
PL375256A1 (en) 2002-08-09 2005-11-28 Astra Zeneca Ab 1,2,4-oxadiazoles as modulators of metabotropic glutamate receptor-5
PL2910551T3 (pl) 2003-04-11 2017-09-29 Ptc Therapeutics, Inc. Związki kwasu 1,2,4-oksadiazolobenzoesowego i ich zastosowanie do supresji mutacji nonsensownych i leczenia choroby
WO2005077373A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
MX2007004479A (es) * 2004-10-13 2007-06-18 Ptc Therapeutics Inc Compuestoss para supresion sin sentido y metodos para su uso.
US20090176837A1 (en) 2005-07-12 2009-07-09 Sony Corporation Compounds with activity at retinoic acid receptors
EP2304366A2 (en) 2008-05-30 2011-04-06 Foster Wheeler Energia Oy Method of and system for generating power by oxyfuel combustion
KR101220182B1 (ko) * 2009-02-25 2013-01-11 에스케이바이오팜 주식회사 치환된 아졸 유도체 화합물, 이를 포함하는 약제학적 조성물 및 이를 이용한 파킨슨씨 병 치료방법
GB0915196D0 (en) * 2009-09-01 2009-10-07 King S College London Therapeutic compounds and their use
WO2011072281A1 (en) 2009-12-11 2011-06-16 Ptc Therapeutics, Inc. Methods for treating methylmalonic acidemia
GB201403093D0 (en) 2014-02-21 2014-04-09 Cancer Rec Tech Ltd Therapeutic compounds and their use
EP3233842B1 (en) * 2014-12-17 2025-03-26 King's College London Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (rarb) agonists

Also Published As

Publication number Publication date
US10385044B2 (en) 2019-08-20
US20200131165A1 (en) 2020-04-30
US20210130337A1 (en) 2021-05-06
CA2970574C (en) 2023-09-19
EP3233842B1 (en) 2025-03-26
EP3233842C0 (en) 2025-03-26
CN107207488A (zh) 2017-09-26
US11401265B2 (en) 2022-08-02
AU2015367531B2 (en) 2020-04-30
KR102526625B1 (ko) 2023-04-27
IL252882A0 (en) 2017-08-31
CA2970574A1 (en) 2016-06-23
US10752616B2 (en) 2020-08-25
ES3029609T3 (en) 2025-06-24
CN107207488B (zh) 2020-11-17
JP2017537967A (ja) 2017-12-21
BR112017012588A2 (pt) 2018-11-13
EP3233842A1 (en) 2017-10-25
US9994559B2 (en) 2018-06-12
BR112017012588B1 (pt) 2023-11-07
US20190010146A1 (en) 2019-01-10
WO2016097004A1 (en) 2016-06-23
IL252882B (en) 2020-04-30
BR112017012588B8 (pt) 2024-02-15
AU2015367531A1 (en) 2017-07-06
KR20170097125A (ko) 2017-08-25
US20170327489A1 (en) 2017-11-16

Similar Documents

Publication Publication Date Title
JP6596090B2 (ja) レチノイン酸受容体ベータ（ＲＡＲβ）アゴニストとしてのビシクロヘテロアリール−ヘテロアリール−安息香酸化合物
US10196358B2 (en) KCNQ2-5 channel activator
KR20090007740A (ko) 헤테로 화합물
TW200901961A (en) Substituted fused-ring compounds for inflammation and immune-related uses
TW200900397A (en) Tricyclic compounds as matrix metalloproteinase inhibitors
JP2011503095A (ja) 精神障害の処置におけるａｌｄｈ−２インヒビター
JPWO2004080943A1 (ja) シンナミルアルコール誘導体化合物およびその化合物を有効成分として含有する薬剤
CN110709394B (zh) 可用作alcat1抑制剂的化合物
US11584741B2 (en) Crystalline forms of 4-(5-(4,7-dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl)benzoic acid and processes for their preparation
WO2002102780A1 (en) Tetrahydroquinoline derivative compound and drug containing the compound as active ingredient
US20220267308A1 (en) Modulators of Excitatory Amino Acid Transporters and Methods Using Same
JPWO2003042194A1 (ja) カルボン酸誘導体化合物およびその化合物を有効成分として含有する薬剤

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20171117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20171117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181205

TRDD Decision of grant or rejection written
A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190829

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190903

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190927

R150 Certificate of patent or registration of utility model

Ref document number: 6596090

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250